Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30693705 | 0.90 | ALDH1A1 (0.55) | ALDH1A1MAOBKDM4ELMNARAB9A | |
| SCHEMBL6989572 | 0.90 | ALDH1A1 (0.55) | ALDH1A1MAOBKDM4ELMNARAB9A | |
| SCHEMBL22491455 | 0.89 | MAOB (0.53) | ALDH1A1RECQLMAOBKDM4ELMNA | |
| SCHEMBL5922423 | 0.89 | ALDH1A1 (0.57) | ALDH1A1MAOBKDM4ELMNARAB9A | |
| SCHEMBL10876065 | 0.88 | ALDH1A1 (0.53) | ALDH1A1RECQLMAOBKDM4ELMNA | |
| SCHEMBL13883739 | 0.87 | MAOB (0.64) | ALDH1A1MAOBKDM4ELMNARAB9A | |
| SCHEMBL7162438 | 0.85 | MAOB (0.62) | ALDH1A1MAOBKDM4ELMNARAB9A | |
| SCHEMBL48418 | 0.85 | ALDH1A1 (0.70) | ALDH1A1RECQLKMT2AGAA | |
| SCHEMBL14359006 | 0.85 | MAOB (0.53) | ALDH1A1MAOBKDM4ELMNARAB9A | |
| SCHEMBL900772 | 0.84 | MAOB (0.56) | ALDH1A1MAOBKDM4ELMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-12195490-B2 | STRAD-binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-14 | — | — | US | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| CN-115916966-A | STRAD binding agents and uses thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| US-11608337-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230040299-A1 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2023-02-09 | — | — | US | disclosed |
| EP-1349852-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | Sugen, Inc. (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20030176528-A1 | Photosensitive resin composition, dry film, and workpiece using the same | MITSUI CHEMICALS, INC. (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030069297-A1 | 4-aryl substituted indolinones | SUGEN, INC. | 2003-04-10 | — | — | US | disclosed |
| US-6495568-B1 | TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-6476258-B1 | Process for producing aryloxyacetic acids | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-11-05 | — | — | US | disclosed |
| WO-2002055517-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | CUI JINGRONG (US) | 2002-07-18 | — | — | WO | disclosed |
| EP-1099692-A1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2001-05-16 | — | — | EP | disclosed |
| EP-1067108-A2 | Process for producing aryloxyacetic acids | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-01-10 | — | — | EP | disclosed |
| EP-1036062-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | Pfizer Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029667-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | ALDH1A1 223/4885RECQL 1238/4885MAOB 650/4885 |
| US-20030069297-A1 | 4-aryl substituted indolinones | CDK5, CAMK4, TNK2 | ALDH1A1 1671/4885RECQL 3241/4885MAOB 1182/4885 |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | ALDH1A1 3440/4885RECQL 3168/4885MAOB 2139/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | ALDH1A1 3415/4885RECQL 3194/4885MAOB 2124/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | ALDH1A1 3415/4885RECQL 3194/4885MAOB 2124/4885 |
| US-20230040299-A1 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | ALDH1A1 2706/4885RECQL 1153/4885MAOB 2245/4885 |
| US-12195490-B2 | STRAD-binding agents and uses thereof | STRAP, STRA6, PLAUR | ALDH1A1 3678/4885RECQL 1597/4885MAOB 1610/4885 |
| US-11608337-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | ALDH1A1 223/4885RECQL 1238/4885MAOB 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.